The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director's Dealings

10 Jan 2024 07:00

RNS Number : 1385Z
Cellular Goods PLC
10 January 2024
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

10 January 2024

Cellular Goods PLC

("Cellular Goods" or "The Company")

Director's Dealings

 

Cellular Goods (LSE: CBX), a UK-based company pioneering the use of lab-based and biosynthetic production methods for wellness and sustainability solutions, announces that Michael Edwards (Executive Director of Cellular Goods) has purchased a total of 2,500,000 ordinary shares in the Company ("Ordinary Shares"), the details of which are set out in the notification below. Following this purchase, Michael Edwards holds a total of 8,000,000 Ordinary Shares, representing 1.33 per cent of the Company's issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Edwards

2.

Reason for the Notification

a)

Position/status

Executive Director

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cellular Goods PLC

b)

LEI

213800IXPX4Z2MKX2U28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares

Identification Code

GB00BK964W87

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

0.417 pence per Ordinary Share

2,500,000 Ordinary Shares

d)

Aggregated information:

· Aggregated volume

· Price

 

2,500,000 Ordinary Shares

0.417 pence per Ordinary Share

e)

Date of the transaction

09 January 2024

f)

Place of the Transaction

London Stock Exchange

 

 

 

For further information please contact:

Cellular Goods

Michael Edwards

Director

via FSCF +44 7572 873 300

First Sentinel Corporate Finance (FSCF)

Investor Relations

Rebecca Noonan

IR@cellular-goods.com

Media Relations

Rebecca Noonan

Media@cellular-goods.com

Corporate Broker & Advisor

Brian Stockbridge

 

+44 7572 873 300

 

 

+44 7572 873 300

 

 

+44 7858 888 007

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

 

 

About Cellular Goods PLC:

Cellular Goods is pioneering the use of lab-based and biosynthetic production methods for wellness and sustainability solutions. The Company launched with a focus on efficacy led and science-backed products utilising biosynthetics, and now employs its expertise across two verticals: premium next-generation cannabinoid skincare products, and carbon sequestration-as-a-service through its wholly owned business division, King Tide Carbon, which utilises biosynthetic algae and seaweed to provide scalable carbon removal. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDZGGMKLGGDZM
Date   Source Headline
7th Nov 20067:02 amRNSDirector/PDMR Shareholding
25th Sep 20069:11 amRNSInterim Results
9th Aug 200610:43 amRNSAGM Statement
26th Jun 20067:01 amRNSFinal Results
28th Apr 200610:10 amRNSGrant of Options
21st Apr 200611:25 amRNSDirector/PDMR Shareholding
3rd Mar 20061:00 pmRNSAdmission to AIM-Amendment
3rd Mar 200612:23 pmRNSAdmission to AIM
7th Feb 20064:55 pmRNSSchedule 1 - Cubus Lux
7th Feb 20067:01 amRNSAcquisition
30th Sep 20051:33 pmRNSInterim Results
25th Jul 20053:25 pmRNSDirector/PDMR Shareholding
20th Jul 20057:00 amRNSOpening of a Third Casino
19th Jul 20056:09 pmRNSChange of Adviser
19th Jul 20056:09 pmRNSDirectorate Change
21st Mar 200512:07 pmRNSAnnual Report and Accounts
6th Jan 20055:52 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.